|
|
 |
|
Ceregene, Inc., a biotechnology company located in San Diego, CA,
is focused on the discovery and development of novel gene therapies
for the treatment of neurological disorders including Alzheimer's
and Parkinson's disease. The company was launched in January 2001
as a majority-owned subsidiary of Cell Genesys following the acquisition
of Neurologic Gene Therapeutics, a private start-up company based
in San Diego. In exchange for approximately 60 percent ownership
of the new company, Cell Genesys contributed $10 million to Ceregene
as well as access to technology and patents in the central nervous
system (CNS) gene therapy area. Following the completion of Ceregene's
Series B financing in August 2004, our ownership percentage decreased
to approximately 25 percent. Ceregene is currently evaluating its gene therapy for Alzheimer's disease and Parkinson's disease in Phase I clinical trials.
For additional information about Ceregene, please visit their corporate
website at www.ceregene.com |
|
